HANX, a trailblazing leader in women’s health and wellness, is thrilled to announce that it has raised £250,000 in its latest funding round. With a rapidly growing community of over 100,000 engaged members, HANX is on a mission to connect every major life stage of women’s health, providing a comprehensive range of gynae-designed sexual and reproductive products—from direct-to-consumer essentials to innovative prescription treatments and enriched content. Founded by former Goldman Sachs investment banker Farah Kabir and gynaecology expert Dr Sarah Welsh, HANX has quickly established itself as a trusted brand with a distinctive twist. Its core product line, which includes pleasure-focused options like sensitive condoms, lubricant, and the bestselling toy, Cindy, resonates strongly with women seeking both utility and empowerment in their intimate care.
The new funds will be strategically deployed to expand HANX’s product offerings and enhance its pioneering same-day-dispatch pharmacy service, which discreetly delivers hormonal contraception, the morning after pill, and intimate care treatments. Additionally, the investment is set to accelerate the rollout of groundbreaking initiatives such as HANX’s weight management programme, which incorporates safe, effective GLP-1 medications like Mounjaro (tirzepatide) and Wegovy (semaglutide). This move will support women in achieving their personal health goals across various life stages. Complementing its robust e-commerce presence, HANX continues to revolutionise in-store experiences by partnering with major UK retailers—being the only challenger brand available in over 2,000 high street stores including Boots, Sainsbury’s, Tesco, and WHSmith. Looking ahead, HANX is gearing up to expand its direct-to-consumer operations in the US and other global markets, underscoring its commitment to transform women’s health on a worldwide scale.
